- 100+ clinical sites in Germany, Poland, Bulgaria, Romania
- 150+ investigators in renal disease indications
- Completion of two clinical programs for biosimilar Erythropoetin zeta, branded as Silapo®/Retacrit®
- Immunogenicity trials
- Therapeutic equivalence trials
- Pharmacokinetic trials in patients
Renal failure and renal anemia
- five phase III trials in 1800 patients on haemodialysis
Chronic Kidney Disease
- two phase III trials in 1050 patients